



## Château Haut-Brion 2015 – A 30-Year Investment Yielding 8.2% UPDATE #1

Current Price (6x75cl)	<b>£2,700-£2,900</b>
Robert Parker	<b>100</b>
Price per Point	<b>£27</b>
Price Target (6x75cl) in 2044	<b>£21,500</b>
Implied Price performance	<b>8.2% CAGR</b>

- **Haut-Brion 2015** is the **cheapest 100-point First Growth** in the World. But **Haut-Brion 1989** (also 100 points) is one of the more expensive.
- Analysing the 'forward curve' for Haut-Brion 100-point wines implies a **8.2% annual return** for almost 30 years for Haut-Brion 2015.
- 30-Year US Treasury Inflation Protected bonds ("TIPS") only yield 0.97%. UK equities in last 20 years returned only 3.2% after inflation.
- **Drinking window** for Haut-Brion 2015 is to **2075!**

### UPDATE TO NOTE FIRST PUBLISHED on 21<sup>st</sup> MAY 2018

- In recent note recommending the 100 point RP **Haut-Brion 2015**, we presented analysis showing how we expected the 2015 to perform given where the 100 point **Haut-Brion 1989** was currently trading.
- That note, published on 21st May 2018, used £19,000 as the Market Price for Haut-Brion 1989. But at the end of last week the 1989 **traded up to £25,000** for 12x75cl on the Liv-ex exchange - a rise of 32% in just two weeks.
- Based on the new current price for Haut-Brion 1989 we are revising up our Target Price for Haut-Brion 2015 to **£21,500** (6x75cl) in 2044 (when the 2015 will be as old as the 1989 is now).
- The expected total CAGR is now projected for Haut-Brion 2015 is now projected to be **8.23%**.
- We re-iterate our **Strong Buy** recommendation on **Haut-Brion 2015** around the £2,700-2,800 level (6x75cl) IB.

## IMPORTANT NOTICE

This report has been issued or approved for issue by an entity forming part of Cru (as defined below) and has been forwarded to you solely for your information and should not be considered as an offer or solicitation of an offer to sell, buy or subscribe to any securities or any derivative instrument or any other rights pertaining thereto ("financial instruments"). This report is intended for use by professional or business investors only. This report may not be reproduced without the consent of Cru.

The information and opinions expressed in this report have been compiled from sources believed to be reliable, but, neither Cru, nor any of its directors, officers, or employees accepts liability from any loss arising from the use hereof or makes any representations as to its accuracy and completeness. Any opinions, forecasts or estimates herein constitute a judgement as at the date of this report. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or estimates. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance. This information is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the product or products mentioned. Cru is not agreeing to nor is it required to update the opinions, forecasts or estimates contained herein.

The value of any products mentioned in this report can fall as well as rise. Foreign currency denominated products are subject to fluctuations in exchange rates that may have a positive or adverse effect on the value, price or income of such products.

This report does not have regard to the specific instrument objectives, financial situation and the particular needs of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any products or investment strategies discussed in this report.

Cru (or its directors, officers or employees) may, to the extent permitted by law, own or have a position in the products of any company or related company or products referred to herein, and may add to or dispose of any such position or may make a market or act as a principal in any transaction in such products. Directors of Cru may also be directors of any of the companies mentioned in this report. Cru (or its directors, officers or employees) may, to the extent permitted by law, act upon or use the information or opinions presented herein, or research or analysis on which they are based prior to the material being published. Cru may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them.

For the purposes of this disclaimer, "Cru" shall mean: (i) Cru London Limited; (ii) Cru Asia Limited and (iii) from time to time, in relation to Cru London Limited and/or Cru Asia Limited, the ultimate holding company of that entity, a subsidiary (or a subsidiary of a subsidiary) of that entity, a holding company of that entity or any other subsidiary of that holding company, and any affiliated entity of any such entities.

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or disclosed to another party, without the prior written consent of an entity within Cru. Products referred to in this research report may not be eligible for sale in those jurisdictions where an entity within Cru is not authorised or permitted by local law to do so. In particular, Cru does not allow the redistribution of this report to non-professional investors or persons outside the jurisdictions referred to above and Cru cannot be held responsible in any way for third parties who effect such redistribution or recipients thereof. © 2018.